Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Assets (2019 - 2025)

UroGen Pharma (URGN) has disclosed Return on Assets for 7 consecutive years, with 0.8% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Assets fell 36.0% year-over-year to 0.8%, compared with a TTM value of 0.8% through Dec 2025, down 36.0%, and an annual FY2025 reading of 0.63%, down 8.0% over the prior year.
  • Return on Assets was 0.8% for Q4 2025 at UroGen Pharma, up from 0.84% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.4% in Q3 2024 and bottomed at 1.06% in Q1 2021.
  • Average Return on Assets over 5 years is 0.73%, with a median of 0.79% recorded in 2021.
  • The sharpest move saw Return on Assets skyrocketed 58bps in 2024, then plummeted -44bps in 2025.
  • Year by year, Return on Assets stood at 0.87% in 2021, then grew by 5bps to 0.83% in 2022, then soared by 34bps to 0.55% in 2023, then grew by 21bps to 0.43% in 2024, then tumbled by -84bps to 0.8% in 2025.
  • Business Quant data shows Return on Assets for URGN at 0.8% in Q4 2025, 0.84% in Q3 2025, and 0.68% in Q2 2025.